Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 159,588 275,693 319,053 656,089
Total Sell Value $13,270,852 $23,760,160 $27,661,182 $61,420,002
Total People Sold 5 6 7 7
Total Sell Transactions 10 21 27 56
End Date 2024-03-10 2023-12-08 2023-06-09 2022-06-09

   
Records found: 2582
  Page 28 of 104  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-05-17 4 OE $38.59 $723,563 D/D 18,750 309,350     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-05-16 4 AS $89.13 $1,671,131 D/D (18,750) 290,600     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-05-16 4 OE $38.59 $723,563 D/D 18,750 309,350     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-05-15 4 AS $88.29 $1,655,434 D/D (18,750) 290,600     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-05-15 4 OE $38.59 $723,563 D/D 18,750 309,350     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-05-14 4 AS $89.22 $1,672,851 D/D (18,750) 290,600     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-05-14 4 OE $38.59 $723,563 D/D 18,750 309,350     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-05-11 4 AS $88.42 $1,657,856 D/D (18,750) 290,600     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-05-11 4 OE $38.59 $723,563 D/D 18,750 309,350     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-05-10 4 AS $89.59 $1,679,794 D/D (18,750) 290,600     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-05-10 4 OE $38.59 $723,563 D/D 18,750 309,350     -
   Mueller Brian SVP, Corporate Controller   •       –      –    2018-05-10 4 AS $89.50 $219,275 D/D (2,450) 15,396     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2018-05-07 4 AS $85.96 $26,562 D/D (309) 52,914     -
   Baffi Robert EVP, Technical Operations   •       –      –    2018-04-30 4 A $68.78 $21,254 D/D 309 84,838     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2018-04-30 4 A $68.78 $11,487 D/D 167 62,781     -
   Davis George Eric EVP, General Counsel   •       –      –    2018-04-30 4 A $68.78 $21,254 D/D 309 88,364     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2018-04-30 4 A $68.78 $21,254 D/D 309 157,101     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-04-30 4 A $68.78 $21,254 D/D 309 290,600     -
   Mueller Brian SVP, Corporate Controller   •       –      –    2018-04-30 4 A $68.78 $19,740 D/D 287 17,846     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2018-04-30 4 A $68.78 $21,254 D/D 309 53,223     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-04-24 4 AS $82.29 $822,887 D/D (10,000) 290,031     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-04-24 4 OE $38.59 $385,900 D/D 10,000 300,031     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-04-23 4 AS $82.58 $825,811 D/D (10,000) 290,031     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2018-04-23 4 OE $38.59 $385,900 D/D 10,000 300,031     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2018-04-23 4 AS $82.15 $908,497 D/D (11,059) 62,543     -
  2582 Records found
  Previous  20  21  22  23  24  25  26  27  28  29  Next   
  Page 28 of 104
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us